FENNEC director granted options for 20,000 shares

FENNEC PHARMACEUTICALS INC. director Marco Maria Brughera received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. director Marco Maria Brughera received a grant of stock options as part of his compensation. On June 10, 2026, he was awarded a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share, fully vested on the grant date. Following this grant, his reported option holdings increased to 235,545 derivative securities, indicating this is a routine equity incentive award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Brughera Marco Maria

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	20,000	$8.70	$174K

Holdings After Transaction: Stock Option — 235,545 contracts (Direct)

Footnotes (2)

1. F1. On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
2. F2. The option is 100% vested on date of grant.

Key Figures

Option grant size: 20,000 shares Exercise price: $8.70 per share Post-grant derivative holdings: 235,545 options +2 more

5 metrics

Option grant size 20,000 shares Non-qualified stock option granted June 10, 2026

Exercise price $8.70 per share Strike price for 20,000-share option grant

Post-grant derivative holdings 235,545 options Total derivative securities following the transaction

Grant date June 10, 2026 Date option was granted and fully vested

Option expiration June 10, 2036 Expiration date of the granted stock option

Key Terms

non-qualified stock option, Equity Incentive Plan, fully vested, exercise price, +1 more

5 terms

non-qualified stock option financial

"Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Equity Incentive Plan financial

"pursuant to the issuer's Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

fully vested financial

"The option is 100% vested on date of grant"

exercise price financial

"to purchase 20,000 shares ... at an exercise price of $8.70"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"total_shares_following_transaction 235545.0000 derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FENNEC PHARMACEUTICALS INC. (FENC) director Marco Brughera report on this Form 4?

Marco Brughera reported receiving a grant of stock options to buy 20,000 FENNEC PHARMACEUTICALS common shares. The options were awarded on June 10, 2026 at an exercise price of $8.70 per share and are part of his equity-based compensation under the company’s incentive plan.

Is the June 10, 2026 FENC Form 4 for an insider stock purchase or a compensation grant?

The Form 4 reflects a compensation-related grant, not an open-market stock purchase. Brughera received a non-qualified stock option to purchase 20,000 common shares at $8.70 per share, fully vested on the grant date, under FENNEC PHARMACEUTICALS’ Equity Incentive Plan.

What are the key terms of Marco Brughera’s new FENC stock options?

The grant covers 20,000 common shares at an exercise price of $8.70 per share. It is a non-qualified stock option, fully vested on June 10, 2026, and is exercisable until its stated expiration date of June 10, 2036, according to the filing footnotes.

How many FENNEC PHARMACEUTICALS derivative securities does Marco Brughera hold after this grant?

After the June 10, 2026 grant, Brughera is reported to hold 235,545 derivative securities in the form of stock options. This total includes the newly granted 20,000-share option and provides context for the scale of this single compensation award in his overall option position.

When do Marco Brughera’s newly granted FENC stock options vest and expire?

The options are 100% vested on the June 10, 2026 grant date, meaning they are immediately exercisable. According to the filing, these non-qualified stock options carry an expiration date of June 10, 2036, giving a 10-year window during which they can be exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 05:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brughera Marco Maria

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(1)	$8.7	06/10/2026		A		20,000		06/10/2026(2)	06/10/2036	Common shares	20,000	$8.7	235,545	D

Explanation of Responses:

1. On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

2. The option is 100% vested on date of grant.

	/s/ Marco Brughera	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)